• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不列颠哥伦比亚省基于收入的药物保险覆盖范围:对药品可及性的影响。

Income-based drug coverage in British Columbia: the impact on access to medicines.

作者信息

Caetano Patricia A, Raymond Colette B, Morgan Steve, Yan Lixiang

机构信息

Centre for Health Services and Policy Research, University of British Columbia, Vancouver, BC.

出版信息

Healthc Policy. 2006 Nov;2(2):e154-69.

PMID:19305697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2585444/
Abstract

BACKGROUND AND OBJECTIVES

In May 2003, the government of British Columbia adopted income-based pharmacare, replacing an age-based program. Stated policy goals included the maintenance or enhancement of access to necessary medicines. This study examines the policy impact on access to two widely used drugs for chronic risk factors (antihypertensives and statins).

METHODS

Data on incident antihypertensive and statin prescriptions between 1997 and 2004 were extracted from PharmaNet. Incident antihypertensive users were those who filled a first prescription after residing in the province for at least two years prior to the initial prescription date. The number of patients who ceased to fill a contiguous series of prescriptions (within 120 days of one another) was used as a measure of apparent discontinuation or interruption of therapy. We used time series analysis to test for changes in incident use and discontinuation.

RESULTS

Between 1997 and 2004, 530,167 BC residents initiated therapy with an antihypertensive, and 264,904 BC residents initiated therapy with a statin. The 2003 policy change had no statistically significant impact on incident use of antihypertensives or statins, when stratified by age or income. Similarly, the 2003 policy did not change the rate of apparent discontinuations of therapy across age and income groups. However, a co-payment introduced in 2002 did increase end-of-year seasonality in apparent discontinuations in seniors--a finding that deserves further research.

DISCUSSION

The 2003 transition to income-based pharmacare in British Columbia did not result in significant changes in access to, or continuation of, prescriptions to treat two leading chronic risk factors.

摘要

背景与目的

2003年5月,不列颠哥伦比亚省政府采用了基于收入的药物保险计划,取代了基于年龄的计划。既定的政策目标包括维持或加强必要药物的可及性。本研究考察了该政策对两种广泛用于慢性风险因素的药物(抗高血压药和他汀类药物)可及性的影响。

方法

从PharmaNet中提取了1997年至2004年间抗高血压药和他汀类药物的新发病例处方数据。新发病例抗高血压药使用者是指在初始处方日期前在该省居住至少两年后首次开具处方的人。将停止连续开具一系列处方(彼此间隔120天内)的患者数量用作治疗明显中断或中止的衡量指标。我们使用时间序列分析来检验新发病例使用情况和停药情况的变化。

结果

1997年至2004年间,530,167名不列颠哥伦比亚省居民开始使用抗高血压药进行治疗,264,904名不列颠哥伦比亚省居民开始使用他汀类药物进行治疗。按年龄或收入分层时,2003年的政策变化对抗高血压药或他汀类药物的新发病例使用情况没有统计学上的显著影响。同样,2003年的政策也没有改变各年龄和收入组中明显停药率。然而,2002年引入的共付费用确实增加了老年人年末明显停药的季节性——这一发现值得进一步研究。

讨论

2003年不列颠哥伦比亚省向基于收入的药物保险计划的转变并未导致治疗两种主要慢性风险因素的处方的可及性或持续性发生显著变化。

相似文献

1
Income-based drug coverage in British Columbia: the impact on access to medicines.不列颠哥伦比亚省基于收入的药物保险覆盖范围:对药品可及性的影响。
Healthc Policy. 2006 Nov;2(2):e154-69.
2
Income-based drug coverage in British Columbia: the impact on private and public expenditures.不列颠哥伦比亚省基于收入的药物保险覆盖范围:对私人和公共支出的影响。
Healthc Policy. 2006 Nov;2(2):e129-53.
3
Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.不列颠哥伦比亚省基于收入的药物保险覆盖范围:给不列颠哥伦比亚省及加拿大其他地区的经验教训。
Healthc Policy. 2006 Nov;2(2):115-27.
4
Income-based drug coverage in british columbia: towards an understanding of the policy.不列颠哥伦比亚省基于收入的药物保险:对该政策的理解
Healthc Policy. 2006 Nov;2(2):92-108.
5
Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.不列颠哥伦比亚省基于收入的药物保险覆盖范围:对经济负担分配的影响。
Healthc Policy. 2006 Nov;2(2):e170-86.
6
The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.不列颠哥伦比亚省从基于年龄的处方药覆盖转为基于收入的覆盖的再分配效应。
Health Policy. 2011 Jul;101(2):185-94. doi: 10.1016/j.healthpol.2010.12.005. Epub 2011 Jan 20.
7
Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.加拿大不列颠哥伦比亚省从基于年龄的处方药保险向基于收入的处方药保险过渡的分配后果。
Health Econ. 2008 Dec;17(12):1379-92. doi: 10.1002/hec.1337.
8
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.基于参考定价的血管紧张素转换酶抑制剂对药物利用的影响。
CMAJ. 2002 Mar 19;166(6):737-45.
9
Using policy simulation to predict drug plan expenditure when planning reimbursement changes.在规划报销变更时,使用政策模拟来预测药品计划支出。
Pharmacoeconomics. 2005;23(10):1021-30. doi: 10.2165/00019053-200523100-00005.
10
The impact of medication reviews by community pharmacists.社区药剂师进行用药评估的影响。
J Am Pharm Assoc (2003). 2016 Sep-Oct;56(5):513-520.e1. doi: 10.1016/j.japh.2016.05.002.

引用本文的文献

1
Universal Pharmacare and Contraceptive Dispensations Among Youth.青少年中的全民医保与避孕药具发放
JAMA Pediatr. 2025 Aug 18. doi: 10.1001/jamapediatrics.2025.2585.
2
Pharmaceutical policies: effects of regulating drug insurance schemes.药品政策:规范药品保险计划的影响
Cochrane Database Syst Rev. 2022 May 3;5(5):CD011703. doi: 10.1002/14651858.CD011703.pub2.
3
Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs.基于收入的共付率能否改善差距?品牌药和仿制药选择的案例。
BMC Health Serv Res. 2019 Nov 1;19(1):780. doi: 10.1186/s12913-019-4598-8.
4
Pharmaceutical policies: effects of cap and co-payment on rational use of medicines.药品政策:封顶价和共付额对合理用药的影响。
Cochrane Database Syst Rev. 2015 May 8;2015(5):CD007017. doi: 10.1002/14651858.CD007017.pub2.
5
Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.不列颠哥伦比亚省基于收入的药物保险覆盖范围:给不列颠哥伦比亚省及加拿大其他地区的经验教训。
Healthc Policy. 2006 Nov;2(2):115-27.
6
Income-based drug coverage in british columbia: towards an understanding of the policy.不列颠哥伦比亚省基于收入的药物保险:对该政策的理解
Healthc Policy. 2006 Nov;2(2):92-108.
7
British Columbia's PharmaCare Program: fair or foul?不列颠哥伦比亚省的药物福利计划:是公平还是不公平?
Healthc Policy. 2006 Nov;2(2):10-4.
8
Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.不列颠哥伦比亚省基于收入的药物保险覆盖范围:对经济负担分配的影响。
Healthc Policy. 2006 Nov;2(2):e170-86.
9
Income-based drug coverage in British Columbia: the impact on private and public expenditures.不列颠哥伦比亚省基于收入的药物保险覆盖范围:对私人和公共支出的影响。
Healthc Policy. 2006 Nov;2(2):e129-53.

本文引用的文献

1
Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.不列颠哥伦比亚省基于收入的药物保险覆盖范围:给不列颠哥伦比亚省及加拿大其他地区的经验教训。
Healthc Policy. 2006 Nov;2(2):115-27.
2
Income-based drug coverage in british columbia: towards an understanding of the policy.不列颠哥伦比亚省基于收入的药物保险:对该政策的理解
Healthc Policy. 2006 Nov;2(2):92-108.
3
Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.不列颠哥伦比亚省基于收入的药物保险覆盖范围:对经济负担分配的影响。
Healthc Policy. 2006 Nov;2(2):e170-86.
4
Income-based drug coverage in British Columbia: the impact on private and public expenditures.不列颠哥伦比亚省基于收入的药物保险覆盖范围:对私人和公共支出的影响。
Healthc Policy. 2006 Nov;2(2):e129-53.
5
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.2005年加拿大高血压教育计划关于高血压管理的建议:第二部分——治疗
Can J Cardiol. 2005 Jun;21(8):657-72.
6
Persistence with hypertension treatment among community-dwelling BC seniors.不列颠哥伦比亚省社区居住老年人高血压治疗的持续性
Can J Clin Pharmacol. 2004 Fall;11(2):e267-73. Epub 2004 Dec 13.
7
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.血脂异常管理与心血管疾病预防建议:2003年更新摘要
CMAJ. 2003 Oct 28;169(9):921-4.
8
Adherence with statin therapy in elderly patients with and without acute coronary syndromes.老年急性冠脉综合征患者与非急性冠脉综合征患者他汀类药物治疗的依从性
JAMA. 2002;288(4):462-7. doi: 10.1001/jama.288.4.462.
9
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.基于参考定价的血管紧张素转换酶抑制剂对药物利用的影响。
CMAJ. 2002 Mar 19;166(6):737-45.
10
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.血管紧张素转换酶抑制剂参考定价的结果
N Engl J Med. 2002 Mar 14;346(11):822-9. doi: 10.1056/NEJMsa003087.